Baxter International Inc. with ticker code (BAX) have now 13 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The target price High/Low ranges between $54.00 and $30.00 suggesting an average analyst share price target price of $42.15. (at the time of writing). Given that the stocks previous close was at $37.15 and the analysts are correct then there would likely be a percentage uptick in value of 13.5%. The 50 day MA is $34.61 and the 200 day moving average is $37.54. The total market capitalization for the company now stands at 18.84B. The stock price is currently at: $36.93 USD
The potential market cap would be $21,376,656,669 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $29.55 and a 3.71% return on assets.
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s segments include Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia-Pacific), and Hillrom. The Americas, EMEA and APAC segments provide a portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals, and surgical hemostat and sealant products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.
